Related Experiment Video
Updated: Jun 19, 2026
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia
Bernice L Z Oh1, Natasha Vinanica2, Desmond M H Wong2
1Viva-University Children's Cancer Center, Khoo Teck Puat-National University Children's Medical Institute, National University Hospital, National University Health System; Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore.
Chimeric antigen receptor (CAR) T-cell therapy shows promise for T-cell acute lymphoblastic leukemia (T-ALL). Challenges include identifying suitable targets and avoiding CAR T-cell self-elimination, with CD7 emerging as a potential target.
Area of Science:
- Immunotherapy
- Oncology
- Cellular Therapy
Background:
- Chimeric antigen receptor (CAR) T-cell therapy is effective for B-cell malignancies.
- T-cell acute lymphoblastic leukemia (T-ALL) lacks targets like CD19 and CD22, posing treatment challenges.
- Outcomes for refractory T-ALL are poor, necessitating novel therapeutic approaches.
Purpose of the Study:
- To explore potential targets for CAR T-cell therapy in T-ALL.
- To review CAR configurations and early clinical results for T-ALL treatment.
- To address challenges in developing CAR T-cells for T-ALL.
Main Methods:
- Discussion of potential CAR T-cell targets for T-ALL, emphasizing CD7.
- Review of CAR T-cell configurations relevant to T-ALL.
- Analysis of early clinical data for CAR T-cell therapy in T-ALL.
Main Results:
- Malignant and normal T cells share antigens, complicating CAR T-cell development.
- CAR T-cells targeting T-ALL may face self-elimination and manufacturing issues.
- CD7 is identified as a promising target for CAR T-cell therapy in T-ALL.
Conclusions:
- CAR T-cell therapy holds potential for T-ALL, but technical hurdles remain.
- Targeting CD7 is a key strategy for overcoming challenges in T-ALL CAR T-cell therapy.
- Further research and clinical trials are needed to optimize CAR T-cell therapy for T-ALL.
Related Concept Videos
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...